nf kappa b inhibitors pipeline insight

DelveInsight’s, “NF-kappa B Inhibitors Pipeline Insight, 2026” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in NF-kappa B Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also 2026 the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

NF-kappa B Inhibitors Understanding

NF-kappa B Inhibitors Overview

NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) inhibitors are agents that suppress the activity of the NF-κB family of transcription factors, which are central regulators of inflammation, immunity, cell survival, and proliferation. Aberrant or sustained NF-κB activation is implicated in numerous inflammatory, autoimmune, and neoplastic diseases. NF-κB inhibitors act at different levels of the signaling cascade—preventing pathway activation, nuclear translocation, DNA binding, or transcriptional activity—thereby dampening pathological gene expression.
Structurally, NF-κB comprises a family of related proteins belonging to the Rel family, including RelA (p65), RelB, c-Rel, p50, and p52, which form various homo- or heterodimers. These proteins share a conserved Rel homology domain responsible for DNA binding, dimerization, and interaction with inhibitory proteins known as IκBs. In resting cells, NF-κB dimers are sequestered in the cytoplasm through association with IκB proteins, which mask their nuclear localization signals and prevent gene transcription.
Functionally, NF-κB acts as a master transcriptional regulator that controls the expression of a wide range of genes involved in immune and inflammatory responses, such as cytokines, chemokines, adhesion molecules, and acute-phase proteins. It also regulates genes involved in cell survival, proliferation, and apoptosis inhibition, thereby maintaining tissue homeostasis and immune defense. While transient activation of NF-κB is protective, sustained activation leads to excessive inflammation, immune dysregulation, and enhanced cell survival signals that contribute to disease progression.
NF-κB signaling is primarily mediated through two major pathways: the canonical and non-canonical pathways. The canonical pathway is activated by pro-inflammatory stimuli such as tumor necrosis factor-α, interleukin-1, toll-like receptor ligands, and microbial products, leading to activation of the IκB kinase (IKK) complex. This results in phosphorylation and proteasomal degradation of IκB, allowing NF-κB dimers, mainly p65/p50, to translocate into the nucleus and initiate gene transcription. The non-canonical pathway, in contrast, is activated by a restricted set of immune receptors and depends on NF-κB-inducing kinase and IKKα, leading to processing of p100 to p52 and nuclear translocation of RelB/p52 complexes, which are important for lymphoid organ development and adaptive immune responses.
NF-κB inhibitors play a significant role in disease management by attenuating aberrant NF-κB activation and the resulting pathological gene expression. In inflammatory and autoimmune disorders such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease, NF-κB inhibition reduces cytokine production and immune cell activation, thereby limiting tissue damage. In cancer, where constitutive NF-κB activation promotes tumor cell survival, proliferation, angiogenesis, and resistance to apoptosis, inhibitors can enhance sensitivity to chemotherapy and suppress tumor progression. Additionally, in neurodegenerative, cardiovascular, and metabolic diseases, NF-κB inhibitors help mitigate chronic inflammation and downstream tissue injury, highlighting their broad therapeutic relevance across multiple disease areas.

"NF-kappa B Inhibitors Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the NF-kappa B Inhibitors pipeline landscape is provided which includes the disease overview and NF-kappa B Inhibitors treatment guidelines. The assessment part of the report embraces, in depth NF-kappa B Inhibitors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, NF-kappa B Inhibitors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Discover the latest NF-kappa B Inhibitors pipeline insights , emerging therapies, and clinical advancements shaping the future of treatment in 2026.

NF-kappa B Inhibitors Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence NF-kappa B Inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve NF-kappa B Inhibitors.

NF-kappa B Inhibitors Emerging Drugs Analysis

This segment of the NF-kappa B Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

NF-kappa B Inhibitors Emerging Drugs

NE3107: BioVie Inc.

NE3107 is an orally bioavailable, BBB-permeable, insulin-sensitizer that is also anti-inflammatory. In addition, it is not immunosuppressive and has a low risk of drug-to-drug interaction. NE3107 has the potential to reduce symptoms of long COVID, including fatigue and cognitive dysfunction. Persistently circulating viral spike proteins are believed to trigger TLR-4 driven activation of NFkB and the subsequent expression of inflammatory cytokines (IL-6, TNF, IFNg). NE3107 has been shown to modulate the activation of NFkB and thus modulate inflammation. NE3107 is also being investigated for Alzheimer’s disease and Parkinson’s disease. BioVie has conducted and reported efficacy data on its Phase III randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild-to-moderate AD. Currently, the drug is in Phase III stage of its clinical development for the treatment of Alzheimer’s disease.

YIV-906: Yiviva

YIV-906 (formerly known as PHY906 or KD018) is a patented, orally administered investigational drug that acts as a pan-adjuvant improving the efficacy and safety for a broad spectrum of cancer drugs and regimens (including chemotherapies, immunotherapies, radiation, and cell therapies). YIV-906 has been studied in nine clinical trials in solid tumors (hepatocellular carcinoma, pancreatic cancer, colorectal cancer, and rectal cancer) with data demonstrating the potential for YIV-906 to improve overall survival and/or progression-free survival and reduce non-hematological toxicities (including diarrhea, nausea, vomiting, fatigue, and hand-foot syndrome). The FDA has granted YIV-906 two Orphan Drug Designations (ODD) for the treatment of hepatocellular carcinoma and pancreatic cancers. Currently, the drug is in the Phase II stage of clinical development for the treatment of patients with Advanced Hepatocellular Carcinoma and Colorectal cancer.

ILB-202: Ilias Bio

ILB-202 is an engineered exosome therapeutic containing the anti-inflammatory protein super-repressor IκB (srlκB), designed to inhibit NF-κB translocation into the nucleus and thereby reduce inflammatory responses. Developed by ILIAS Biologics, ILB-202 directly targets core cytosolic inflammation signaling, offering potentially fewer off-target effects than conventional upstream pathway inhibitors. It has undergone Phase I clinical trials evaluating safety and tolerability in healthy volunteers, particularly for conditions like acute kidney injury (AKI) related to cardiac surgery.

Further product details are provided in the report……..

NF-kappa B Inhibitors Therapeutic Assessment

This segment of the report provides insights about the different NF-kappa B Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in NF-kappa B Inhibitors

There are approx. 10+ key companies which are developing the therapies for NF-kappa B Inhibitors. The companies which have their NF-kappa B Inhibitors drug candidates in the most advanced stage, i.e. phase III include, BioVie Inc.

Phases

DelveInsight’s report covers around 12+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of 
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

NF-kappa B Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral 
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer 
• Gene therapy

NF-kappa B Inhibitors Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

NF-kappa B Inhibitors Clinical Trial Activities 

The NF-kappa B Inhibitors Pipeline report provides insights into different NF-kappa B Inhibitors Clinical Trial candidates within phase II, I, preclinical and discovery stage. It also analyses NF-kappa B Inhibitors therapeutic drugs key players involved in developing key drugs. 

NF-kappa B Inhibitors Pipeline Development Activities

The NF-kappa B Inhibitors Clinical Trial analysis report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging NF-kappa B Inhibitors drugs.

NF-kappa B Inhibitors Report Insights

• NF-kappa B Inhibitors Pipeline Analysis
• NF-kappa B Inhibitors Therapeutic Assessment
• NF-kappa B InhibitorsUnmet Needs
• Impact of NF-kappa B Inhibitors Drugs

NF-kappa B Inhibitors Report Assessment

• NF-kappa B Inhibitors Pipeline Product Profiles
• NF-kappa B Inhibitors Therapeutic Assessment
• NF-kappa B Inhibitors Pipeline Assessment
• Inactive drugs assessment
• NF-kappa B Inhibitors Market Unmet Needs

Discover actionable insights into the NF-kappa B Inhibitors market trends , epidemiology trends, and forecast through 2034 to stay ahead in emerging therapies.

Key Questions Answered In The NF-kappa B Inhibitors Pipeline Report:

• Current Treatment Scenario and Emerging Therapies:
• How many companies are developing NF-kappa B Inhibitors drugs?
• How many NF-kappa B Inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of NF-kappa B Inhibitors?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the NF-kappa B Inhibitors therapeutics? 
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? 
• What are the clinical studies going on for NF-kappa B Inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• BioVie, Inc
• Yiviva
• Ilias Bio
• SFA THERAPEUTICS, INC.
• EntreChem

Key Products

• NE3107
• YIV-906
• ILB-202
• SFA 001
• EC-70124